Dr. Hannes Hentze currently holds the positon of Associate Director of the Translational Sciences. He is responsible for the Biomarker Development, Mass Spectrometry, and in vivo pharmacology functions of EDDC.
Having established his networks and built his knowledge of the industry across 20 years in various roles, Dr. Hentze brings to the table 20 years of experience in academic research, biotech companies (S*BIO, ES Cell International, ASLAN), and in the pharmaceutical industry (MSD).
A pre-clinical scientist and in vivo pharmacologist by training, Dr Hentze’s expertise includes preclinical oncology and diabetes mouse models, integration of innovative biomarkers in pre-clinical programs, large animal models for cardiovascular disease and dyslipidaemia, as well as rodent models for cell therapy applications. He has published over 35 peer-reviewed articles, reviews and book chapters in the areas of liver disease, redox regulation, stem cell therapy, diabetes and oncology (H = 27)
Dr. Hannes Hentze holds a PhD in Biochemical Pharmacology from the University of Konstanz (Germany). In addition, he has recently obtained an executive MBA from INSEAD.